Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Trastuzumab (Herceptin®) is recommended as an option for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. This submission covers the licence extensions for treatment with trastuzumab:
AWMSG is of the opinion that trastuzumab (Herceptin®) is suitable for specialist only prescribing within NHS Wales for the above indication. |
|||
|
|||
Medicine details |
|||
| Medicine name | trastuzumab (Herceptin®) | ||
| Formulation | powder for concentrate for solution for infusion | ||
| Reference number | 1066 | ||
| Indication | Treatment of patients with HER2-positive early breast cancer following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. Treatment of patients with HER2-positive early breast cancer in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin |
||
| Company | Roche Products Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 0312 | ||
| NMG meeting date | 04/01/2012 | ||
| AWMSG meeting date | 08/02/2012 | ||
| Ratification by Welsh Government | 16/05/2012 | ||
| Date of issue | 18/05/2012 | ||
| Date of last review | 30/08/2016 | ||